CRNX Stock Analysis: Buy, Sell, or Hold?
CRNX - Crinetics Pharmaceuticals, Inc.
$42.23
3.55 (9.18%)
▲
5d:
+20.69%
30d:
+29.5%
90d:
+15.48%
HOLD
MODERATE Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Aug 06, 2026
Get Alerted When CRNX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD - EXTENDED: CRNX is 12.7% above its trading range ($37.48). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
📊 HOLD - EXTENDED: CRNX is 12.7% above its trading range ($37.48). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
In-depth Analysis How we analyze
Valuation Analysis: CRNX is currently trading at $42.23, which is considered extended relative to its 30-day fair value range of $33.62 to $37.48.
Technical Outlook: Technically, CRNX is in a downtrend. The price is approaching resistance at $42.30. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 9.2% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $83.14 (+96.9%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, CRNX is in a downtrend. The price is approaching resistance at $42.30. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 9.2% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $83.14 (+96.9%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$33.62 -
$37.48
Company Quality Score
64/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
45.8%
All Signals
- BEARISH: Price significantly overextended (+12.7% above its trading range)
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+9.2%)
- BULLISH: Trading 96.9% below Wall St target ($83.14)
Trading Range Analysis
30-Day Trading Range
$33.62 -
$37.48
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$34.71
Resistance Level
$42.30
Current Trend
Downtrend
Technical data as of
Jul 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-10.03
Wall Street Target
$83.14
(+96.9%)
Revenue Growth (YoY)
2873.4%
Share & Embed Analysis
Last updated: July 02, 2026 10:48 PM ET
Data refreshes hourly during market hours. Next update: 11:48 PM
Data refreshes hourly during market hours. Next update: 11:48 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CRNX showing a specific setup today?
Insider Activity (6 Months)
1
Buys
8
Sells
Net
INSIDERS SELLING
Recent Transactions
Jeff E Knight
SELL
85163 shares
2026-04-08
Jeff E Knight
SELL
9911 shares
2026-03-16
Richard Scott Struthers
SELL
21981 shares
2026-03-16
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 56 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$549 | 59 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$110 | 61 BUY |
|
CLDX
Celldex Therapeutics Inc |
STRONG BUY
15 analysts |
$58 | 57 HOLD |
|
VERA
Vera Therapeutics Inc |
STRONG BUY
14 analysts |
$78 | 59 HOLD |
